Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only a fools complain about being a fool.
The fat lady has not sang a note yet.
If you need a loss, take it.
Chiding others for not being down is worthless.
It helps nothing to make a decision and then later blastphemising.
Do oil companies sit and whine when they drill a dry hole?
Life is a waste if you make it so.
Kick at the dirt and call out names.
The only person who hurts you here is yourself.
It is a choice.
For those who feel taken, time is a wastin'.
Sell your shares to me.
Nice to know you are the Guardian Angel of this thread. Without your motherly wisdom, all these people here would be lost.
Do you even know what this company does?
Of course not.
Once again you need to get back to stealing identities and scamming senior citizens. At least that way you can still be the only one on the planet who sees your face; the one in the mirror of course.
OK, Genious.
Froggie,
Worktoplay is leaps and bounds above your petty trash. If you took the time to read his full post you would realize how idiotic you sound.
It is amusing that a genious such as yourself would be fool enough to (supposedly) invest in a penny stock and then bash it for years on end.Hmmmmm......
Gee, poor little froggie was dumb enough to invest in Dr Frudakis and now he hates him and likes to call him a liar and thief. Pretty ignorant stuff for a GENIOUS.
Or......just maybe..........you are bashing for other reasons?
I thought GENIOUSES such as yourself would understand that time is precious and that whining, name calling, crying in your beer and trashing other people smarter than you is a pathetic waste of valuable time.
Which is it? Foolish investor gone sour after buying a penny stock, or are you just foolish?
Johnnyfiber,
Your presence here is a benefit to the rest of us, and thank you for sharing your tid bits of valuable information.
On another note, I have sympathy with Chris as there are a few of us who have been here 7 long years. Yet I have been part of several corporations and without going into great detail, everything I see in management strategy makes sense and in some cases even relief.
Of late I was concerned about percentages of ownership and it seemed to me that DNAPrint might be in danger of being exposed to takeover vulnerability or share manipulation that could damage the company by intent, and in deciphering the share availability to management in the future, my concerns
were adressed.
It is imperative that control of this company is protected and I find the moves both wise and prudent. Whereas Chris has obviously soured a bit on Tony and Richard, I have total confidence in their committment to shareholders and the obvious goal of company success, and the way that this team has weathered adversity in changing markets and biotech innovation limitations with meager funds is impressive.
Gomez is key, and everything is laid out in front of us sans the smoking gun. It's all there. Now the rest of the world has to catch up.
And it will.
How many names do you have.....other than "PAID BASHER"????
Guess anything would seem dainty to the likes of a sweathog.
Froggie,
Yes, it is an opinion, and your 'thesis' presented here on a penny stock message board is going to take a bit more than a discussion with sciguy.
You would need to prove it as fact and therefore predict that it will never be true.
But, the world is flat and man landing on the moon will never happen.
Yet lo and behold, frogs can now talk so anything can happen.
Besides, your "facts" are immediately discounted as there is an axe-grinding influence due to your hate for the one man who knows more than you, Dr Tony Frudakis.
Good day.
"Ancestry is a very imprecise attempt to locate a genetic variance in a bio-geographical subgroup when it cannot be located by other mean."
Oh, you forgot something....
"IMHO"
Hey Scummer.
Could you please help save the planet a waste of oxygen and go play on the freeway?
Which alias of total idiocy do you think works the best?
Lookout lest your basher level of intelligence transfers over to the rest of your loser life.
Stocky,
I am 100% confident now that this company will make it and that we will see every penny invested times more in return. That IMO.
I think Chris would be a little easier on you if you had not bashed after you sold the first time, and well, you really do push the enthusiasm, but that doesn't bother me.
If people buy into a penny stock it is their deal solely, no matter who they listen to or how much.
Yes, we are going places.
Laying low and long & strong with DNAPrint. 7 years and over the hump.
Ditto.
Er, excuse me Trebeg,
but it is Stockchild, not Stockboy.
So Bag,
Now you are an ignorant patsy. So much for Froggie saying he is diplomatic.
What a sick little ego that thinks every conversation is only about his thin little line of reasoning.
He IS a liar and is a deceptive little person.
Don't waste your time.
And all that is left is a disembodied alias basher.....
yeah, stockboy, you can stay. It's everyone's board.
The sooner DNAPrint goes totally broke is the sooner we won't have to put up with all ourselves. Then we will all be happy, right stockboy?
Stockchild,
I may be as worthless as Teats on a boar hog, but I do own a few million shares of this here penny stock and I have no plans to sell, so, unlike you, I have a reason to be here.
At least "teats" don't hang around day after day whining like a crybaby and bashing like a amatuer.
Now, change your diapers and eat your creamed sweet potatoes.
Then go out into the real world and do something good for a change.
Bag.....
May I make a suggestion?
There is absolutely no reason to converse with Frog, unless your ego requires it. The obsession to be right about an event that hasn't occurred yet and of which we have no real facts is an indication of an agenda or a desperate insecurity to prove himself top dog. He consistently splits hairs and makes it look like he knows what he is talking about, but he really doesn't.
This nothing but circumspection about events which are yet to occur, and the abusive nature Frog so slimily slips into his deceptive recipe by talking down to you and others is reason enough to not have discourse with his dirty little agenda.
He is a coward. He calls the managers of this company liars and thieves from behind the curtain, yet acts so logical and pragmatic in thinking process, a virtual conflict of ethical and mature stature.
He constanly calls you and others gut-punch names by using his dirty little nouns and adjectives; "fantasize", "imagination", blah, blah, blah. No social grace, just the constant view from the top of his little kingdom.
A sale of an asset can be part of a restructure, and a "restructure" can be defined by any combination of events. What matters is if it is successful, not how much it is argued over.
Re-organization? Restructure? Funds?
Need these subjects be approached with abuse to other people?
Then you have no reason to be here. You have permission to leave.
Or are you going to keep complaining about how foolish you have been to "buy in"?
Which is it gonna be?
Interesting how Froggie has to bring up my name before his crystal ball reading.
If I say the sun will shine tomorrow and it does, then my false ego will be satiated for the time being.
If it doesn't shine then I can disappear into the night.
What good his prediction does for all of you, I cannot quite fathom at this time, yet I hope that it clears up those issues some of you have torn your hair out over while engaged in this penny stock. Good luck to you.
The biomedical process is long and arduous.
We will either win or lose with this bet.
I think Frog wastes his whole diatribe by calling Gabriel a liar. Even if he was a liar, it is the wrong thing to do.
Amazing how a person could be so smart, yet have no tact. It destroys the point you are trying to make. Ego always shows.
If the Frog has an agenda, or just hates this company, or whatever,..........
I do hope it helps his self worth to prove himself to us.
That;s me, high blood pressure, spit slinging mad man, over and out.
Frog.
Your history of deception is proof in itself. You have lied, and are a liar. If the idiots pump some stupid 20X crap, it does not in the least dampen the manipulations and self-righteous stance you have taken over the years.
Looks like Mr Fiber likes some of your work. More power to you guys.
Btw, you still haven't caught on to what I was implying.
You have sneered and looked down on all who have conversed with you.
You have no diplomacy.
Even if you are right 99.999% of the time, your demeaning discourse followed by the usual nasty quip at the end of most posts shows that you may know about everything under the sun except people themselves. That's an ego problem.
Plain and simple.
Have a glorious evening.
Froggie,
"spit-slinging nitwit". Hmmm. So you have started to call out names and I am the one who is throwing the tantrum, eh?
I have folliowed the thread. Maybe you should read my post a little closer. When people speculate without any facts, you perpetuate it, at the very least. I never said you started it.
I guess that being the intelligent king-of-the-mountain here doesn't necessarily hold you to any higher standards.
I do apologize for one thing, though.
I meant to say " an electrical engineer who THINKS he's a securities analyst, banker, accountant, dna scientist, and inheritant of a higher developed gene pool"
Over and out.
Frog,
It is you who is ignorant, and you who is the liar.
Please show us the text of the board meeting you sat in at DNAPrint so that we may be advised on your inside knowledge of exactly what is going on at the company. (Or are you going to try and claim you were talking of "some other company"?)
Then again,it may be are you going on the same information that was given over the phone when the word "restructure" was mentioned in passing? Plus other tidbits?
I have already gone to the trouble of explaining to your highness that "restructure" can mean many things, good or bad. Any further ponderance henceforth is, as I said, pure speculation and you are, among others, just wasting your time,(unless you have an agenda)on the subject.
For a super-human intelligent stud like yourself, you should be the last person to be throwing around your "opinions", as that is exactly what you try to bash others for doing.
There is no choice but to wait and see. Do you even get it?
And you call me ignorant. That coming from an electrical engineer/securities analyst/accountant/banker/DNA scientist.
Hilarious.
Complete and utter supposition.
Not an ounce of fact but stated as so.
Froggie......
Always smarter than everyone else and talking down on them.
Always puts others down as if he knows all and they are idiots. But now Senor Froggie has all the answers about restructuring, when it is actually all conjecture and guesswork. He doesn't know anything about what the company is doing, at all.
His scary figures are all based on his negative bashing and he just sits here day in and day out, King of the Mountain, spitting out Frog-nuggets of deceptive self wisdom on all the little peons below his super-intelligent level.
Why is he here?
Why is he here?
Why?
Stockchild(or paid basher),
Go back to your other alias's or play in the sandbox.
Your trash is now obvious, even to those who defended the ridiculous notion that you were just plain stupid.
Have you tried scamming senior citizens yet?
There's gold in them hills, Mr Basher.
Onco,
I don't either. But a couple of the names are familiar, and Lancaster was the Moffitt official signing on the collaboration w/ DNAP in 2004. He is one of the authors of this one.
Just posting info. Not jumping to any conclusions.
Moffitt & Dnaprint: 3 years/2004
4. CONFIDENTIALITY - Except as expressly set forth herein, any confidential information exchanged by the Parties shall be held in confidence ("Confidential Information"). The Parties agree that for a period of three (3) years from the expiration or termination of this Agreement, all information exchanged by the parties and marked as Confidential and oral disclosures that have been reduced to writing within thirty (30) days of the disclosure and marked as Confidential
shall be covered by this Agreement. The Parties further agree that for a period of three (3) years after the termination of this Agreement, Confidential Information from either Party will be maintained in confidence with the same
degree of care that they employ with respect to their own information. However, neither Party shall have any obligation with respect to Confidential Information, which is:
Here is at least some of t RESEARCH COLLABORATION AGREEMENT
This Agreement entered into on this ____day of __________ 2004 ("Effective
Date") by and between DNAPRINT GENOMICS, INC., a for profit corporation located
at 900 Cocoanut Avenue, Sarasota, FL 34236 ("the Company") and the H. LEE
MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., a Florida not for profit
corporation organized pursuant to Section 1004.43, Florida Statutes, located at
12902 Magnolia Drive, Tampa, Florida 33612 ("Moffitt") Company, and Moffitt are
hereinafter each individually referred to as a "Party" and collectively as the
"Parties."
WHEREAS, the Company is the assignee of all rights, title and interest
in certain proprietary mapping strategy and patented Ancestry Informative
Markers and OTHER PROPRIETARY TECHNOLOGIES, TOOL AND KNOW-HOW THAT ARE THE
SUBJECT OF VARIOUS PATENT PENDING APPLICATIONS ("COMPANY IP");
WHEREAS, Moffitt and the University of South Florida ("USF") have
executed a Research Addendum to its Affiliation Agreement that ensures that USF
provide principal investigators and other services to Moffitt for Moffitt-based
research and further grants to Moffitt the authority to negotiate and enter into
agreements respecting the protection and commercialization of certain
Intellectual Property in the name of Moffitt.
WHEREAS, the USF and/or Moffitt are the assignees of all rights, title
and interest in certain technology and biological materials including patented
and pending patent applications. ("USF/Moffitt IP")
WHEREAS, it is in the mutual interest of Company and Moffitt to
participate and collaborate in certain projects ("Projects") which are outlined
generally, attached hereto and incorporated by reference as Exhibit A;
WHEREAS, the Parties acknowledge that Exhibit A may be amended from
time to time to add additional studies to the Project.
WHEREAS, the Company, and certain Moffitt and/or University employees
which will be designated for each Project ("Principal Investigators") will
collaborate to ensure that each Project is carried out according to the scope of
work set forth for each Project; and
WHEREAS, the Parties are interested in collaborating with each other to
study methods to determine responses to anticancer drugs utilizing specialized
genetic tests. The Moffitt Labs will use gene expression techniques while the
Company Labs will utilize SNP's techniques. --------------
NOW, THEREFORE, the Parties agree as follows:
1. SCHEDULE The Projects shall be carried out from November 17, 2003 to November
17, 2006 ("Project Period") unless sooner terminated by written notice pursuant
to Section 10 of this Agreement. This Agreement may be renewed by the Parties,
as a new Agreement or by amendments to this Agreement.
<PAGE>
2. PRINCIPAL INVESTIGATORS - The research is to be conducted under the direction
of the Principal Investigators. It will be the responsibility of each Principal
Investigator to transmit and receive information from the Parties, to coordinate
visits and arrange all other matters pertinent to the Project.
3. FUNDING - Neither Party is obligated to fund the research of the other Party.
Hence, Company and Moffitt shall each be responsible for their own expenses
incurred in the performance of the Projects, unless otherwise agreed to in
writing. Moffitt makes no representations that they will fund any clinical
trials that may ensue from the Projects. Funding for the clinical trials will be
dependent upon each Principal Investigator's ability to financially support such
trials and or support from Company or another third party.
4. CONFIDENTIALITY - Except as expressly set forth herein, any confidential
information exchanged by the Parties shall be held in confidence ("Confidential
Information"). The Parties agree that for a period of three (3) years from the
expiration or termination of this Agreement, all information exchanged by the
parties and marked as Confidential and oral disclosures that have been reduced
to writing within thirty (30) days of the disclosure and marked as Confidential
shall be covered by this Agreement. The Parties further agree that for a period
of three (3) years after the termination of this Agreement, Confidential
Information from either Party will be maintained in confidence with the same
degree of care that they employ with respect to their own information. However,
neither Party shall have any obligation with respect to Confidential
Information, which is:
(i) independently developed by the receiving Party as evidenced by
written records, without the benefit of the disclosure, or is already
known to the receiving Party at the time of disclosure;
(ii) publicly known or becomes publicly known without the wrongful act
or breach of this Agreement by the receiving Party;
(iii) rightfully received by the receiving Party from a third party on
a non-confidential basis; or
(iv) is required to be disclosed by law or court order.
4.1 Any combination of features or disclosures shall not be deemed to fall
within the foregoing exclusions merely because individual features are published
or available to the general public or in the rightful possession of a Party,
unless the combination itself and principle of operation are published or
available to the general public or in the rightful possession of such Party.
5. RESEARCH REPORTS AND PUBLICATION Each Party shall promptly, fully and
confidentially inform the other Parties of the results of the research conducted
hereunder. Company and Moffitt will consult on mutually agreed times and
intervals regarding the progress of the Project.
5.1 Each Party reserves the right to publish information resulting from the
Projects. The Parties may jointly publish information related to the Projects
with authorship determined by the usual academic standards. Moffitt and/or USF
<PAGE>
shall have the right to use any facts, findings or other research information
resulting from the Project for research and educational purposes only. The
Parties agree that they shall give each other the opportunity to review any
proposed manuscript thirty (30) days prior to submission for publication in
order that Confidential Information if any, may be removed or patent
applications may be timely filed.
6. PUBLICITY None of the Parties shall use the name of another Party in any form
of advertising or promotion without the prior written approval of the other. The
Parties may however, acknowledge each other's support in matters such as
publications. In any such statement, the relationship of Parties shall be
accurately and appropriately described.
7. PATENT RIGHTS It is recognized and understood that the Parties are engaged in
proprietary research and development activities. Both Parties have rights to
their own separate intellectual property, and may further have materials and
technologies that are the subject of various patent pending
applications,("Background Technology") which are not affected by this Agreement
or by any Amendment to this Agreement. This Agreement in no way confers any
license under any patent or proprietary interests of one Party's Background
Technology to the other Party
7.1 Title to all inventions and discoveries conceived and/or first reduced to
practice solely by Company as a result of these Projects, shall reside with the
Company. Title to all inventions and discoveries conceived and/or first reduced
to practice solely by Moffitt and/or USF shall reside with Moffitt and/or USF.
USF and/or Moffitt and Company shall jointly own title to all inventions and
discoveries made, conceived and/or reduced to practice jointly by the Parties
resulting from these Projects ("Joint Inventions"). All Parties agree to
immediately notify each other in the event an invention is made. Inventorship
shall be determined in accordance with United States Patent Laws.
Notwithstanding any provision herein to the contrary, intellectual property
rights between Moffitt and University shall be governed by the Research Addendum
signed on September 24, 2003.
7.2 The Parties agree that it is in their best interest to commercialize any
Joint Inventions resulting form the Projects. In the event that Joint Inventions
are commercialized, the Parties agree
7.3 Except for the granting of rights to respective governmental agencies as
required by law and the offer of Terms made in this Section 7, the Parties agree
that during the term of this agreement neither party will issue a license
agreement or assign patent rights to any third parties without the prior written
consent of the other Parties.
8. EXCHANGES OF MATERIALS AND DATA All materials including progeny of biological
materials and data exchanged pursuant to the Project shall remain the property
of the providing Party, and shall be used solely for the purposes of this
Agreement. Upon termination of this Agreement, the rights granted under this
Agreement to each other to use the materials and data of each Party by the other
Party shall terminate immediately. The unused portions of the materials will be
returned to the providing Party or will be disposed of as directed by the
providing Party in writing. If a Party desires to use Material exchanged under
this Agreement for research other than the Project, it will obtain prior written
<PAGE>
consent from the other Party, or Parties, by way of an amendment to this
Agreement or by way of a new Agreement.
8.1 Material exchanged under this Agreement is being supplied to the other
Parties with no warranties, expressed or implied, including any warranty of
merchantability or fitness for a particular purpose. Provider makes no
representations that the use of the Research Material will not infringe any
patent or any proprietary rights of third parties. Recipients agree to assume
all liability for damages that arise from the use, storage or disposal of the
Material.
8.2 The Material is for use only by each Party and is NOT FOR USE IN HUMANS. No
specimens of the Material are to be given or made available to any other person
other than the other Party's employees, and are to remain under each Party's
immediate and direct control.
8.3 All Parties assure that any Material exchanged under this Agreement will be
handled safely and labeled, packaged, and transported in accordance with all
applicable laws and regulations.
9.0 REPRESENTION AND WARRRANIES: The parties represent and warrant that they are
legally able to enter into this Agreement and are under no obligations to
acquire approval of any other person or entity to enter into this Agreement.
10.0 INDEPENDENT CONTRACTOR: Company agrees that for the purposes of this
Agreement all services to be provided hereunder, the parties shall be, and shall
be deemed to be, independent contractors and not agents or employees of the
other party. Neither party shall have authority to make any statements,
representations or commitments of any kind, or to take any action which shall be
binding on the other party, except as may be expressly provided for herein or
authorized in writing
10.1 Company shall maintain adequate insurance for the protection of its
personnel housed at Moffitt. The level of insurance is set forth in Exhibit B
attached to this Agreement and incorporated by reference.
10.2 Company agrees that Moffitt shall not be liable for the injuries caused by
Company's employees while house at Moffitt except to the extent that such
injuries were caused by negligent acts or negligent omissions of Moffitt or its
employees.
10.3 Notwithstanding any thing to the contrary, Moffitt shall not have any
liability to Company for any claim of loss of profits, loss of interruption of
business, or for indirect, special or consequencial damages of any kind.
10.4 Company agrees that should any such injury occur that Company shall
immediately notify Moffitt pursuant to Paragraph 12, Notices.
11. NOTICE - Whenever any notice is to be given hereunder, it shall be in
writing and sent to the following address:
<PAGE>
COMPANY: Richard Gabriel
he Moffitt agreement:
GOALS
(Read the last line)
BACKGROUND
THE H. LEE MOFFITT CANCER CENTER
The H. Lee Moffitt Cancer Center - has a substantial program involved in cancer,
has access to a l85,000 patient clinical center and has expertise in the conduct
of clinical trials.
DNAPRINT GENOMICS, INC. - IS A PHARMACOGENOMICS COMPANY WITH PROPRIETARY
TECHNOLOGIES TO STUDY DNA SAMPLES AND DETERMINE CLASSIFIERS TO PREDICT RESPONSES
TO DRUGS.
STUDY PROPOSAL ON COLON CANCER
PRINCIPAL INVESTIGATOR AT MOFFITT: TIM YEATMAN, MD_____________________________
STUDY PROPOSAL ON MULTIPLE MYELOMA
PRINCIPAL INVESTIGATOR AT MOFFITT: DANIEL SULLIVAN, MD__________________________
STUDY PROPOSAL ON CYCLOPHOSPHAMIDE
PRINCIPAL INVESTIGATOR AT MOFFITT: RICHARD M. LUSH, PHD_________________________
STUDY PROPOSAL ON TAXANES
PRINCIPAL INVESTIGATOR AT MOFFITT: JONATHAN M. LANCASTER, MD
That was the abstract. For the full text you have to subscribe to JCO.
Gynecologic Cancer
An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer
Holly K. Dressman, Andrew Berchuck, Gina Chan, Jun Zhai, Andrea Bild, Robyn Sayer, Janiel Cragun, Jennifer Clarke, Regina S. Whitaker, LiHua Li, Jonathan Gray, Jeffrey Marks, Geoffrey S. Ginsburg, Anil Potti, Mike West, Joseph R. Nevins, and Johnathan M. Lancaster
JCO Feb 10 2007: 517–525. [Abstract] [Full Text] [PDF]
An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer
Holly K. Dressman, Andrew Berchuck, Gina Chan, Jun Zhai, Andrea Bild, Robyn Sayer, Janiel Cragun, Jennifer Clarke, Regina S. Whitaker, LiHua Li, Jonathan Gray, Jeffrey Marks, Geoffrey S. Ginsburg, Anil Potti, Mike West, Joseph R. Nevins, Johnathan M. Lancaster
From the Divisions of Gynecologic Surgical Oncology and Cancer Prevention and Control, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Institute for Genome Sciences and Policy, Department of Molecular Genetics and Microbiology, Department of Obstetrics and Gynecology/Division of Gynecologic Oncology, and Departments of Surgery and Medicine, Duke University Medical Center; Institute of Statistics and Decision Sciences, Duke University, Durham, NC; and Institute of Medical Genetics, University Hospital of Wales, Cardiff, United Kingdom
Address reprint requests to Johnathan M. Lancaster, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612; e-mail: lancasjm@moffitt.usf.edu
PURPOSE: The purpose of this study was to develop an integrated genomic-based approach to personalized treatment of patients with advanced-stage ovarian cancer. We have used gene expression profiles to identify patients likely to be resistant to primary platinum-based chemotherapy and also to identify alternate targeted therapeutic options for patients with de novo platinum-resistant disease.
PATIENTS AND METHODS: A gene expression model that predicts response to platinum-based therapy was developed using a training set of 83 advanced-stage serous ovarian cancers and tested on a 36-sample external validation set. In parallel, expression signatures that define the status of oncogenic signaling pathways were evaluated in 119 primary ovarian cancers and 12 ovarian cancer cell lines. In an effort to increase chemotherapy sensitivity, pathways shown to be activated in platinum-resistant cancers were subject to targeted therapy in ovarian cancer cell lines.
RESULTS: Gene expression profiles identified patients with ovarian cancer likely to be resistant to primary platinum-based chemotherapy with greater than 80% accuracy. In patients with platinum-resistant disease, we identified expression signatures consistent with activation of Src and Rb/E2F pathways, components of which were successfully targeted to increase response in ovarian cancer cell lines.
CONCLUSION: We have defined a strategy for treatment of patients with advanced-stage ovarian cancer that uses therapeutic stratification based on predictions of response to chemotherapy, coupled with prediction of oncogenic pathway deregulation, as a method to direct the use of targeted agents.
Supported by the Ovarian Cancer Research Fund, Gynecologic Cancer Foundation's Molly Cade Ovarian Cancer Award, Hearing the Ovarian Cancer Whisper Organization, and the Jacquie Liggett Fellowship in Ovarian Cancer Research.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
sciguy,
"Trying to have a discussion with you is like trying to dance with smoke."
Uh, in case you haven't realized it yet, THAT is his only purpose here, and very likely paid for it. .....
So, you will ALWAYS be 'dancing with smoke" when dealing with the Frog. The creation of doubt is his only protocol.
Or maybe we should feel honored to have an electrical engineer who is also a financial whiz, a scientist more accomplished than Tony Frudakis, and a penny stock hater all in one.
In short,for every cloud of smoke we let him blow onto this thread by perpetuating ambiguity, his exact and only goal is met.
Uh oh, looks like the unkissed prince is hopping around again. Someone must have put Tabasco on his lillypad.
I guess by Frog's answer that he has never owned a business or a corporation so we should take all of his brilliant input on corporate sharestructure and restructure with a grain of sea salt.
Electrical engineer who despises Dr. Frudakis yet owns DNAPrint shares; predicts DNAPrint will close it's doors yet still owns DNAPrint shares. Calls them all liars and thieves yet has never been in the position of running a fledgling biotech with pre-cutting edge technology.
Hmmmm. And I thought I would never feel sorry for this guy...............
I've got more than ten off the tip of my finger.
But first, let's talk about you always referring to my calling you out on your falsehhods as "blowing steam".
As I have mentioned previously, you mistake disgust for anger.
You have the highest propensity to look down on others.
You are ALWAYS right.
You are an Engineer. A scientist.
And now a banker and accountant. Oh, and retired.
You have 5 patents to your name,(it once was 8, but you forgot you said that)
And, you have admitted to Bagger that you would like to see this company fail.
And don't call any of these lies. I read them myself here and on RB.
I may not be near as 'Intelligent" as you, but I do have a good memory when it comes to people like you.
A company may want to restructure so that they can sell a division of the corporation or a certain asset that another entity has interest in. The division or company that is sold off (or just a portion of it) can be in cash, can be used to sway financing, can be traded for restricted shares, etc, etc, all without dillution of share structure or caiitalization.
There is hundred scenarios, some bad for shareholders, some good.
This is why you need to review how value is set.
You forgot "demand"
You also forgot 'Revenues."
I have one question for you. Have you ever owned a company or a corporation?
Let's just tell the truth here, your highness.
Actually, I changed my mind.
I do not trust you.
End of discussion.
Frogdreaming,
Whether your speculations turn out to be correct or not is not the point.
"Restructure" can occurr in many other ways.
I stand by the point that your "facts" on financing are false and misleading.
Funny how you didn't adress THAT.
If you weren't grinding that axe, someone just might listen to you.
Frog,
Pure speculation.
Your "scenario" for discussion was with yourself and we all know what happens when someone tries to "discuss" anything with your highness.
Good day.
Frogdreaming,
This statement you made is totally false:
"Realize that there is no way to have any 'financing' associated with any 'restructuring' that is not dilutive.
Unless there is a philanthropist in the picture, (lol) any financing is going to be in exchange for some type of equity. Any equity that requires 'restructuring' is in the form of finance in exchange for shares."
Guess you have never heard of "revenues".
Most financing on planet earth is paid off by revenues,(which is DNAPrint's goal) and equity is used in most cases as collateral. I have seen restructuring that occurred with financing and a revenue contract that were beneficial to the company. I have done it.
Also, a secretary using the word "restructuring" could mean anything.
Your first statement is false.
Your second statement is false.
They are both misleading.
Whoever sold close to 400k shares, thank you.
I have just lowered my average.
And so it will be....... to the end........
OR to the beginning.